Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
martes, octubre 27
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Tandem Diabetes Care Inc
TNDM
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$18.90
1.47
8.43%
Últ. Act.: Oct 26, 7:42 PM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Ganancias:
Beneficios de Q3 2026 dentro de 9 días de ahora en jue nov 5th, después del cierre del mercado
Tandem Diabetes Care Financials
Tandem Diabetes Care (TNDM) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Tandem Diabetes Care Q2 EPS $(0.31) Beats $(0.32) Estimate, Sales $254.560M Miss $254.978M Estimate
Tandem Diabetes Care (NASDAQ:TNDM) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.32) by 3.13 percent. This is a 60.26 percent increase over losses of $(0.78) per share
Benzinga Newsdesk
PRO
Tandem Diabetes Care Affirms FY2026 Sales Guidance of $1.065B-$1.085B vs $1.074B Est
Tandem Diabetes Care (NASDAQ:TNDM) affirms FY2026 sales outlook from $1.065 billion-$1.085 billion to $1.065 billion-$1.085 billion vs $1.074 billion estimate.
Benzinga Newsdesk
PRO
Tandem Diabetes Care Affirms FY2026 Sales Guidance of $1.065B-$1.085B vs $1.076B Est.
Tandem Diabetes Care (NASDAQ:TNDM) affirms FY2026 sales outlook from $1.065 billion-$1.085 billion to $1.065 billion-$1.085 billion vs $1.076 billion estimate.
Benzinga Newsdesk
PRO
Tandem Diabetes Care Q1 Adj. EPS $(0.30) Beats $(0.45) Estimate, Sales $247.221M Beat $241.125M Estimate.
Tandem Diabetes Care (NASDAQ:TNDM) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.45) by 33.33 percent. This is a 54.55 percent increase over losses of $(0.67) per share
Benzinga Newsdesk
Dow Jumps Over 200 Points After Court's Tariff Ruling: Investor Sentiment Improves, Greed Index Remains In 'Fear' Zone
U.S. stocks rise after Supreme Court decision on tariffs. Fear & Greed index eases but remains in 'Fear' zone.
Avi Kapoor
Tandem Diabetes Shares Rise 33% On Earnings Beat, Margin Expansion, Growth Outlook
Tandem Diabetes stock surges after earnings beat and margin growth, as investors weigh 2026 sales guidance and market momentum.
Vandana Singh
